Skip to main content

Advertisement

SpringerLink
Log in

Immuno- and gene-therapeutic strategies targeted against cancer (mainly focusing on pancreatic cancer)

  • Review Article
  • Published:
Surgery Today Aims and scope Submit manuscript

Abstract

Current treatment modalities of surgical resection and chemotherapy against cancers have improved survival. However, mortality from tumor recurrence remains high. Immunotherapy and gene therapy are potential additions to the treatment arsenal in the care of cancer patients. These novel therapeutic approaches need further investigation in in vitro and in vivo models as they are developed for potential use in humans. Here we reviewed immunotherapies and gene therapies that included clinical trials against cancers (mainly focusing on pancreatic cancer) suggesting the strong possibility of using these novel approaches.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Wingo PA, Tong T, Bolden S. Cancer statistics, 1995. CA Cancer J Clin 1995;45:8–30.

    Article  CAS  PubMed  Google Scholar 

  2. Brennan MF. Surgical therapy and prognosis of soft tissue sarcoma (in German). Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen 1993;64:449–454.

    CAS  PubMed  Google Scholar 

  3. Geer RJ, Brennan MF. Prognostic indicators for survival after resection of pancreatic adenocarcinoma. Am J Surg 1993;165:68–72; discussion 72–3.

    Article  CAS  PubMed  Google Scholar 

  4. Conlon KC, Klimstra DS, Brennan MF. Long-term survival after curative resection for pancreatic ductal adenocarcinoma. Clinicopathologic analysis of 5-year survivors. Ann Surg 1996;223:273–279.

    Article  CAS  PubMed  Google Scholar 

  5. Yeo CJ, Cameron JL. Improving results of pancreaticoduodenectomy for pancreatic cancer. World J Surg 1999;23:907–912.

    Article  CAS  PubMed  Google Scholar 

  6. Yeo CJ, Abrams RA, Grochow LB, Sohn TA, Ord SE, Hruban RH, et al. Pancreaticoduodenectomy for pancreatic adenocarcinoma: postoperative adjuvant chemoradiation improves survival. A prospective, single-institution experience. Ann Surg 1997;225:621–633; discussion 633–6.

    Article  CAS  PubMed  Google Scholar 

  7. Kalser MH, Ellenberg SS. Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection. Arch Surg 1985;120:899–903.

    CAS  PubMed  Google Scholar 

  8. Gastrointestinal Tumor Study Group. Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer. Cancer 1987;59:2006–2010.

    Article  Google Scholar 

  9. Saito I. Gene therapy vector: adenovirus vector (in Japanese). Tanpakushitsu Kakusan Koso 1997;42:1798–1805.

    CAS  PubMed  Google Scholar 

  10. Brody SL, Crystal RG. Adenovirus-mediated in vivo gene transfer. Ann NY Acad Sci 1994;716:90–101; discussion 101–3.

    Article  CAS  PubMed  Google Scholar 

  11. Crystal RG. In vivo and ex vivo gene therapy strategies to treat tumors using adenovirus gene transfer vectors. Cancer Chemother Pharmacol 1999;43:suppl:S90–S99.

    Article  CAS  PubMed  Google Scholar 

  12. Wu Q, Moyana T, Xiang J. Cancer gene therapy by adenovirus-mediated gene transfer. Curr Gene Ther 2001;1:101–122.

    Article  CAS  PubMed  Google Scholar 

  13. Varda-Bloom N, Shaish A, Gonen A, Levanon K, Greenbereger S, Ferber S, et al. Tissue-specific gene therapy directed to tumor angiogenesis. Gene Ther 2001;8:819–827.

    Article  CAS  PubMed  Google Scholar 

  14. Freeman SM, Whartenby KA, Freeman JL, Abboud CN, Marrogi AJ. In situ use of suicide genes for cancer therapy. Semin Oncol 1996;23:31–45.

    CAS  PubMed  Google Scholar 

  15. Hassan W, Sanford MA, Woo SL, Chen SH, Hall SJ. Prospects for herpes-simplex-virus thymidine-kinase and cytokine gene transduction as immunomodulatory gene therapy for prostate cancer. World J Urol 2000;18:130–135.

    Article  CAS  PubMed  Google Scholar 

  16. Nasu Y, Kusaka N, Saika T, Tsushima T, Kumon H. Suicide gene therapy for urogenital cancer: current outcome and prospects. Mol Urol 2000;4:67–71.

    Article  CAS  PubMed  Google Scholar 

  17. van Dillen IJ, Mulder NH, Vaalburg W, de Vries EF, Hospers GA. Influence of the bystander effect on HSV-tk/GCV gene therapy. A review. Curr Gene Ther 2002;2:307–322.

    Article  PubMed  Google Scholar 

  18. Bi WL, Parysek LM, Warnick R, Stambrook PJ. In vitro evidence that metabolic cooperation is responsible for the bystander effect observed with HSV tk retroviral gene therapy. Hum Gene Ther 1993;4:725–731.

    Article  CAS  PubMed  Google Scholar 

  19. Freeman SM, Abboud CN, Whartenby KA, Packman CH, Koeplin DS, Moolten FL, et al. The “bystander effect”: tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res 1993;53:5274–5283.

    CAS  PubMed  Google Scholar 

  20. Schwarzenberger P, Harrison L, Weinacker A, Gaumer R, Theodossiou C, Summer W, et al. Gene therapy for malignant mesothelioma: a novel approach for an incurable cancer with increased incidence in Louisiana. J LA State Med Soc 1998;150:168–174.

    CAS  PubMed  Google Scholar 

  21. Rosenfeld ME, Vickers SM, Raben D, Wang M, Sampson L, Feng M, et al. Pancreatic carcinoma cell killing via adenoviral mediated delivery of the herpes simplex virus thymidine kinase gene. Ann Surg 1997;225:609–618; discussion 618–20.

    Article  CAS  PubMed  Google Scholar 

  22. Aoki K, Yoshida T, Matsumoto N, Ide H, Hosokawa K, Sugimura T, et al. Gene therapy for peritoneal dissemination of pancreatic cancer by liposome-mediated transfer of herpes simplex virus thymidine kinase gene. Hum Gene Ther 1997;8:1105–1113.

    Article  CAS  PubMed  Google Scholar 

  23. Oldfield EH, Ram Z, Culver KW, Blaese RM, DeVroom HL, Anderson WF, et al. Gene therapy for the treatment of brain tumors using intra-tumoral transduction with the thymidine kinase gene and intravenous ganciclovir. Hum Gene Ther 1993;4:39–69.

    Article  CAS  PubMed  Google Scholar 

  24. Hwang HC, Smythe WR, Elshami AA, Kucharczuk JC, Amin KM, Williams JP, et al. Gene therapy using adenovirus carrying the herpes simplex-thymidine kinase gene to treat in vivo models of human malignant mesothelioma and lung cancer. American J Respir Cell Mol Biol 1995;13:7–16.

    CAS  Google Scholar 

  25. Nakada Y, Saito S, Ohzawa K, Morioka CY, Kita K, Minemura M, et al. Antisense oligonucleotides specific to mutated K-ras genes inhibit invasiveness of human pancreatic cancer cell lines. Pancreatology 2001;1:314–319.

    Article  CAS  PubMed  Google Scholar 

  26. Wickstrom E. Oligonucleotide treatment of ras-induced tumors in nude mice. Mol Biotechnol 2001;18:35–55.

    Article  CAS  PubMed  Google Scholar 

  27. Tsuchida T, Kijima H, Hori S, Oshika Y, Tokunaga T, Kawai K, et al. Adenovirus-mediated anti-K-ras ribozyme induces apoptosis and growth suppression of human pancreatic carcinoma. Cancer Gene Ther 2000;7:373–383.

    Article  CAS  PubMed  Google Scholar 

  28. Barton CM, Staddon SL, Hughes CM, Hall PA, O’sullivan C, Klöppel G, et al. Abnormalities of the p53 tumour suppressor gene in human pancreatic cancer. Br J Cancer 1991;64:1076–1082.

    CAS  PubMed  Google Scholar 

  29. Bischoff JR, Kirn DH, Williams A, Heise C, Horn S, Muna M, et al. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 1996;274:373–376.

    Article  CAS  PubMed  Google Scholar 

  30. Heise C, Sampson-Johannes A, Williamu A, McCormick F, Von Hoff DD, Kirn DH. ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat Med 1997;3:639–645.

    Article  CAS  PubMed  Google Scholar 

  31. Mulvihill S, Warren R, Venook A, Adler A, Randlev B, Heise C, et al. Safety and feasibility of injection with an E1B-55 kDa gene-deleted, replication-selective adenovirus (ONYX-015) into primary carcinomas of the pancreas: a phase I trial. Gene Ther 2001;8:308–315.

    Article  CAS  PubMed  Google Scholar 

  32. Cohen EE, Rudin CM. ONYX-015. Onyx Pharmaceuticals. Curr Opin Invest Drugs 2001;2:1770–1775.

    CAS  Google Scholar 

  33. Greten TF, Jaffee EM. Cancer vaccines. J Clin Oncol 1999;17:1047–1060.

    CAS  PubMed  Google Scholar 

  34. Dranoff G, Jaffee E, Lazenby A, Golumbek P, Levitsky H, Brose K, et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA 1993;90:3539–3543.

    Article  CAS  PubMed  Google Scholar 

  35. Toes RE, Bloom RJ, van der Voort E, Offringa R, Melief CJ, Kast WM. Protective antitumor immunity induced by immunization with completely allogeneic tumor cells. Cancer Res 1996;56:3782–3787.

    CAS  PubMed  Google Scholar 

  36. Thomas MC, Greten TF, Pardoll DM, Jaffee EM. Enhanced tumor protection by granulocyte-macrophage colony-stimulating factor expression at the site of an allogeneic vaccine. Hum Gene Ther 1998;9:835–843.

    Article  CAS  PubMed  Google Scholar 

  37. Simons JW. Bioactivity of human GM-CSF gene therapy in metastatic renal cell carcinoma and prostate cancer. Hinyokika Kiyo 1997;43:821–822.

    CAS  PubMed  Google Scholar 

  38. Soiffer R, Lynch T, Mihm M, Jung K, Rhuda C, Schmallinger JC, et al. Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma. Proc Natl Acad Sci USA 1998;95:13141–13146.

    Article  CAS  PubMed  Google Scholar 

  39. Simons JW, Mikhak B, Chang JF, DeMarzo AM, Carducci MA, Lim M, et al. Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer. Cancer Res 1999;59:5160–5168.

    CAS  PubMed  Google Scholar 

  40. Jaffee EM, Schtte M, Gossett J, Morsberger LA, Adler AJ, Thomas M, et al. Development and characterization of a cytokine-secreting pancreatic adenocarcinoma vaccine from primary tumors for use in clinical trials. The cancer journal from Sci Am 1998;4:194–203.

    CAS  Google Scholar 

  41. Jaffee EM, Hruban RH, Biedrzycki B, Laheru D, Schepers K, Sauter PR, et al. Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation. J Clin Oncol 2001;19:145–156.

    CAS  PubMed  Google Scholar 

  42. Thomas AM, Santarsiero LM, Lutz ER, Armstrong TD, Chen YC, Huang LQ, et al. Mesothelin-specific CD8(+) T cell responses provide evidence of in vivo cross-priming by antigen-presenting cells in vaccinated pancreatic cancer patients. J Exp Med 2004;200:297–306.

    Article  CAS  PubMed  Google Scholar 

  43. Laheru D, Lutz E, Burke J, Biedrzycki B, Solt S, Onners B, et al. Allogeneic granulocyte macrophage colony-stimulating factor-secreting tumor immunotherapy alone or in sequence with cyclophosphamide for metastatic pancreatic cancer: a pilot study of safety, feasibility, and immune activation. Clin Cancer Res 2008;14:1455–1463.

    Article  CAS  PubMed  Google Scholar 

  44. Egen JG, Kuhns MS, Allison JP. CTLA-4: new insights into its biological function and use in tumor immunotherapy. Nat Immunol 2002;3:611–618.

    Article  CAS  PubMed  Google Scholar 

  45. Small EJ, Tchekmedyian NS, Rini BI, Fong L, Lowy I, Allison JP. A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer. Clin Cancer Res 2007;13:1810–1815.

    Article  CAS  PubMed  Google Scholar 

  46. Langer LF, Clay TM, Morse MA. Update on anti-CTLA-4 antibodies in clinical trials. Expert Opin Biol Ther 2007;7:1245–1256.

    Article  CAS  PubMed  Google Scholar 

  47. Morse MA, Hobeika AC, Osada T, Serra D, Niedzwiecki D, Lyerly HK, et al. Depletion of human regulatory T cells specifically enhances antigen-specific immune responses to cancer vaccines. Blood 2008;112:610–618.

    Article  CAS  PubMed  Google Scholar 

  48. Kondo H, Hazama S, Kawaoka T, Yoshino S, Yoshida S, Tokuno K, et al. Adoptive immunotherapy for pancreatic cancer using MUC1 peptide-pulsed dendritic cells and activated T lymphocytes. Anticancer Res 2008;28:379–387.

    CAS  PubMed  Google Scholar 

  49. Heemskerk B, Heemskerk B, Liu K, Dudley ME, Johnson LA, Kaiser A, et al. Adoptive cell therapy for patients with melanoma, using tumor-infiltrating lymphocytes genetically engineered to secrete interleukin-2. Hum Gene Ther 2008;19:496–510.

    Article  CAS  PubMed  Google Scholar 

  50. Adams S, O’Neill DW, Nonaka D, Hardin E, Chiriboga L, Siu K, et al. Immunization of malignant melanoma patients with full-length NY-ESO-1 protein using TLR7 agonist imiquimod as vaccine adjuvant. J Immunol 2008;181:776–784.

    CAS  PubMed  Google Scholar 

  51. Bargou R, Leo E, Zugmaier G, Klinger M, Goebeler M, Knop S, et al. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science 2008;321:974–977.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgery II, Yamaguchi University School of Medicine, Ube, Yamaguchi, Japan

    Kiyoshi Yoshimura & Masaaki Oka

  2. Department of Surgery, Johns Hopkins University School of Medicine, 1650 Orleans Street, The Bunting Blaustein Cancer Research Building, Room 442, Baltimore, MD, 21231, USA

    Kiyoshi Yoshimura, Kelly Olino, Barish H. Edil & Richard D. Schulick

Authors
  1. Kiyoshi Yoshimura
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kelly Olino
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Barish H. Edil
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Richard D. Schulick
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Masaaki Oka
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Yoshimura, K., Olino, K., Edil, B.H. et al. Immuno- and gene-therapeutic strategies targeted against cancer (mainly focusing on pancreatic cancer). Surg Today 40, 404–410 (2010). https://doi.org/10.1007/s00595-009-4120-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00595-009-4120-8

Key words

Search

Navigation